| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Peripheral Arterial Disease | 101 | 2026 | 504 | 32.770 |
Why?
|
| Platelet Aggregation Inhibitors | 84 | 2026 | 496 | 15.620 |
Why?
|
| Myocardial Infarction | 89 | 2025 | 1209 | 14.660 |
Why?
|
| Rivaroxaban | 29 | 2026 | 268 | 10.300 |
Why?
|
| Aspirin | 33 | 2026 | 402 | 7.850 |
Why?
|
| Lower Extremity | 29 | 2026 | 440 | 6.490 |
Why?
|
| Stroke | 42 | 2026 | 1262 | 6.350 |
Why?
|
| Factor Xa Inhibitors | 19 | 2026 | 187 | 6.300 |
Why?
|
| Thrombosis | 23 | 2025 | 396 | 6.140 |
Why?
|
| Acute Coronary Syndrome | 34 | 2024 | 295 | 6.020 |
Why?
|
| Lactones | 24 | 2022 | 59 | 5.880 |
Why?
|
| Secondary Prevention | 46 | 2026 | 255 | 5.840 |
Why?
|
| Purinergic P2Y Receptor Antagonists | 27 | 2025 | 71 | 5.670 |
Why?
|
| Fibrinolytic Agents | 17 | 2025 | 290 | 5.620 |
Why?
|
| Vascular Surgical Procedures | 15 | 2026 | 343 | 5.350 |
Why?
|
| Adenosine | 20 | 2023 | 255 | 5.170 |
Why?
|
| Pyridines | 27 | 2022 | 603 | 4.950 |
Why?
|
| Diabetes Mellitus, Type 2 | 30 | 2026 | 2573 | 4.840 |
Why?
|
| Ischemia | 28 | 2026 | 422 | 4.810 |
Why?
|
| Endovascular Procedures | 14 | 2026 | 385 | 4.780 |
Why?
|
| Atherosclerosis | 22 | 2025 | 409 | 4.780 |
Why?
|
| Hemorrhage | 48 | 2026 | 813 | 4.280 |
Why?
|
| Coronary Artery Disease | 19 | 2026 | 743 | 3.850 |
Why?
|
| Treatment Outcome | 113 | 2026 | 11735 | 3.820 |
Why?
|
| Cardiovascular Diseases | 34 | 2026 | 2172 | 3.610 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 14 | 2024 | 438 | 3.440 |
Why?
|
| Aged | 150 | 2026 | 25955 | 3.070 |
Why?
|
| Heart Failure | 28 | 2026 | 2324 | 3.040 |
Why?
|
| Humans | 303 | 2026 | 144667 | 2.950 |
Why?
|
| Venous Thromboembolism | 14 | 2025 | 326 | 2.900 |
Why?
|
| Double-Blind Method | 53 | 2026 | 2033 | 2.890 |
Why?
|
| Drug Therapy, Combination | 29 | 2026 | 1044 | 2.870 |
Why?
|
| Risk Factors | 86 | 2026 | 10796 | 2.800 |
Why?
|
| Troponin I | 10 | 2022 | 73 | 2.790 |
Why?
|
| Glucagon-Like Peptides | 4 | 2025 | 70 | 2.580 |
Why?
|
| Anticholesteremic Agents | 7 | 2024 | 154 | 2.570 |
Why?
|
| Middle Aged | 135 | 2026 | 35971 | 2.500 |
Why?
|
| Anticoagulants | 21 | 2026 | 729 | 2.450 |
Why?
|
| Aortic Diseases | 5 | 2022 | 125 | 2.440 |
Why?
|
| Renal Insufficiency, Chronic | 7 | 2026 | 657 | 2.430 |
Why?
|
| Stroke Volume | 15 | 2026 | 650 | 2.400 |
Why?
|
| Drug-Eluting Stents | 6 | 2026 | 88 | 2.380 |
Why?
|
| Brain Ischemia | 8 | 2022 | 358 | 2.350 |
Why?
|
| Randomized Controlled Trials as Topic | 31 | 2026 | 1742 | 2.260 |
Why?
|
| Thrombolytic Therapy | 8 | 2021 | 161 | 2.150 |
Why?
|
| Male | 166 | 2026 | 72431 | 2.130 |
Why?
|
| Female | 163 | 2026 | 78304 | 1.990 |
Why?
|
| Dyslipidemias | 5 | 2025 | 182 | 1.970 |
Why?
|
| Walking | 9 | 2025 | 542 | 1.930 |
Why?
|
| Risk Assessment | 36 | 2026 | 3729 | 1.900 |
Why?
|
| Atrial Fibrillation | 8 | 2026 | 555 | 1.790 |
Why?
|
| Diabetes Mellitus | 11 | 2023 | 1076 | 1.790 |
Why?
|
| Cholesterol, LDL | 7 | 2024 | 359 | 1.770 |
Why?
|
| Ventricular Function, Left | 6 | 2026 | 536 | 1.660 |
Why?
|
| Hypoglycemic Agents | 14 | 2025 | 1388 | 1.630 |
Why?
|
| Hospitalization | 19 | 2026 | 2446 | 1.550 |
Why?
|
| Intermittent Claudication | 7 | 2025 | 122 | 1.550 |
Why?
|
| Glucosides | 8 | 2020 | 55 | 1.500 |
Why?
|
| Benzhydryl Compounds | 8 | 2020 | 81 | 1.470 |
Why?
|
| ST Elevation Myocardial Infarction | 6 | 2025 | 64 | 1.450 |
Why?
|
| Hypolipidemic Agents | 3 | 2025 | 89 | 1.390 |
Why?
|
| Time Factors | 38 | 2026 | 7140 | 1.330 |
Why?
|
| Blood Coagulation Disorders | 2 | 2023 | 196 | 1.260 |
Why?
|
| Heterocyclic Compounds, 2-Ring | 7 | 2026 | 18 | 1.240 |
Why?
|
| Embolism | 2 | 2022 | 48 | 1.210 |
Why?
|
| Percutaneous Coronary Intervention | 8 | 2025 | 547 | 1.200 |
Why?
|
| Troponin T | 6 | 2022 | 63 | 1.170 |
Why?
|
| Limb Salvage | 9 | 2026 | 73 | 1.160 |
Why?
|
| Follow-Up Studies | 29 | 2026 | 5414 | 1.120 |
Why?
|
| Extremities | 6 | 2021 | 140 | 1.110 |
Why?
|
| Coronary Thrombosis | 4 | 2018 | 25 | 1.110 |
Why?
|
| Biomarkers | 32 | 2026 | 4261 | 1.110 |
Why?
|
| International Classification of Diseases | 2 | 2025 | 147 | 1.010 |
Why?
|
| Postoperative Complications | 4 | 2025 | 2950 | 1.010 |
Why?
|
| Receptors, Thrombin | 5 | 2015 | 13 | 0.990 |
Why?
|
| Piperazines | 8 | 2014 | 378 | 0.980 |
Why?
|
| Glomerular Filtration Rate | 4 | 2026 | 764 | 0.960 |
Why?
|
| Vascular Diseases | 4 | 2023 | 252 | 0.930 |
Why?
|
| Phosphatidylcholine-Sterol O-Acyltransferase | 2 | 2022 | 8 | 0.930 |
Why?
|
| Sterol O-Acyltransferase | 2 | 2022 | 6 | 0.920 |
Why?
|
| Kaplan-Meier Estimate | 16 | 2024 | 967 | 0.920 |
Why?
|
| Electrocardiography | 8 | 2018 | 664 | 0.910 |
Why?
|
| Cardiovascular Agents | 4 | 2022 | 165 | 0.910 |
Why?
|
| Incidence | 18 | 2025 | 2892 | 0.890 |
Why?
|
| Hypercholesterolemia | 2 | 2024 | 93 | 0.880 |
Why?
|
| Incretins | 1 | 2025 | 21 | 0.870 |
Why?
|
| Myocardial Ischemia | 6 | 2021 | 285 | 0.860 |
Why?
|
| Blood Glucose | 2 | 2025 | 2326 | 0.860 |
Why?
|
| Mobile Applications | 2 | 2024 | 197 | 0.850 |
Why?
|
| Prasugrel Hydrochloride | 6 | 2024 | 22 | 0.840 |
Why?
|
| Kidney Diseases | 5 | 2020 | 427 | 0.830 |
Why?
|
| Natriuretic Peptide, Brain | 7 | 2026 | 109 | 0.820 |
Why?
|
| Pyrimidines | 7 | 2026 | 519 | 0.820 |
Why?
|
| Glucagon-Like Peptide 1 | 4 | 2025 | 146 | 0.810 |
Why?
|
| Hyperglycemia | 2 | 2025 | 374 | 0.810 |
Why?
|
| Community Health Workers | 1 | 2025 | 86 | 0.810 |
Why?
|
| Multicenter Studies as Topic | 11 | 2025 | 408 | 0.800 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 2 | 2023 | 92 | 0.800 |
Why?
|
| Chest Pain | 4 | 2017 | 99 | 0.790 |
Why?
|
| Acute Disease | 8 | 2021 | 1029 | 0.780 |
Why?
|
| Aged, 80 and over | 20 | 2026 | 8284 | 0.770 |
Why?
|
| Acetanilides | 6 | 2014 | 11 | 0.770 |
Why?
|
| United States | 29 | 2026 | 16018 | 0.760 |
Why?
|
| Cardiology | 3 | 2022 | 359 | 0.760 |
Why?
|
| Recurrence | 21 | 2024 | 1136 | 0.750 |
Why?
|
| Anterior Wall Myocardial Infarction | 1 | 2022 | 4 | 0.750 |
Why?
|
| Outpatients | 4 | 2025 | 447 | 0.750 |
Why?
|
| Prospective Studies | 23 | 2026 | 7994 | 0.740 |
Why?
|
| Antifibrinolytic Agents | 1 | 2023 | 63 | 0.730 |
Why?
|
| Patient Selection | 3 | 2022 | 727 | 0.730 |
Why?
|
| Quality of Life | 6 | 2025 | 3183 | 0.720 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2025 | 299 | 0.700 |
Why?
|
| Medicare | 10 | 2026 | 899 | 0.700 |
Why?
|
| Proprotein Convertase 9 | 7 | 2021 | 87 | 0.700 |
Why?
|
| Serine Proteinase Inhibitors | 2 | 2020 | 48 | 0.680 |
Why?
|
| Paclitaxel | 2 | 2021 | 256 | 0.670 |
Why?
|
| Disease Management | 2 | 2024 | 650 | 0.660 |
Why?
|
| Beneficence | 1 | 2021 | 20 | 0.660 |
Why?
|
| Myocarditis | 2 | 2019 | 101 | 0.660 |
Why?
|
| Hypertension | 4 | 2025 | 1262 | 0.660 |
Why?
|
| Cerebrovascular Disorders | 2 | 2018 | 106 | 0.660 |
Why?
|
| Dyspnea | 2 | 2020 | 250 | 0.650 |
Why?
|
| Biomedical Research | 2 | 2025 | 712 | 0.650 |
Why?
|
| Platelet Aggregation | 5 | 2023 | 98 | 0.650 |
Why?
|
| Research Subjects | 1 | 2021 | 39 | 0.650 |
Why?
|
| Databases, Factual | 5 | 2024 | 1494 | 0.650 |
Why?
|
| Clinical Trials as Topic | 7 | 2026 | 1056 | 0.640 |
Why?
|
| Neoplasms | 5 | 2026 | 2873 | 0.640 |
Why?
|
| Prognosis | 16 | 2025 | 4312 | 0.640 |
Why?
|
| Personal Autonomy | 1 | 2021 | 59 | 0.630 |
Why?
|
| Diabetes Complications | 2 | 2021 | 223 | 0.630 |
Why?
|
| Renal Insufficiency | 2 | 2021 | 172 | 0.620 |
Why?
|
| Cholesterol | 4 | 2022 | 404 | 0.620 |
Why?
|
| Beverages | 1 | 2020 | 67 | 0.610 |
Why?
|
| Caffeine | 1 | 2020 | 74 | 0.610 |
Why?
|
| Sex Characteristics | 2 | 2023 | 776 | 0.600 |
Why?
|
| Lipoproteins, HDL | 4 | 2024 | 99 | 0.600 |
Why?
|
| Consensus | 2 | 2022 | 475 | 0.590 |
Why?
|
| Leg | 1 | 2021 | 240 | 0.590 |
Why?
|
| Informed Consent | 1 | 2021 | 197 | 0.580 |
Why?
|
| Aortic Aneurysm, Thoracic | 1 | 2020 | 138 | 0.570 |
Why?
|
| Ezetimibe | 1 | 2018 | 24 | 0.570 |
Why?
|
| Syndrome | 5 | 2023 | 379 | 0.560 |
Why?
|
| Patient Care Team | 1 | 2024 | 690 | 0.550 |
Why?
|
| Stents | 4 | 2021 | 557 | 0.550 |
Why?
|
| Cause of Death | 9 | 2026 | 464 | 0.540 |
Why?
|
| Drug Administration Schedule | 10 | 2024 | 779 | 0.540 |
Why?
|
| Smoking Cessation | 3 | 2026 | 436 | 0.530 |
Why?
|
| Blood Platelets | 5 | 2023 | 379 | 0.530 |
Why?
|
| Dose-Response Relationship, Drug | 10 | 2021 | 2019 | 0.530 |
Why?
|
| Diagnostic Imaging | 1 | 2020 | 341 | 0.530 |
Why?
|
| Ovarian Neoplasms | 1 | 2023 | 589 | 0.510 |
Why?
|
| Growth Differentiation Factor 15 | 3 | 2023 | 41 | 0.510 |
Why?
|
| Absorbable Implants | 3 | 2026 | 37 | 0.510 |
Why?
|
| Proportional Hazards Models | 11 | 2021 | 1322 | 0.500 |
Why?
|
| Death, Sudden, Cardiac | 4 | 2026 | 230 | 0.500 |
Why?
|
| Heparin | 3 | 2023 | 243 | 0.490 |
Why?
|
| Factor XI | 3 | 2025 | 11 | 0.490 |
Why?
|
| Survival Rate | 6 | 2021 | 2089 | 0.490 |
Why?
|
| Mineralocorticoid Receptor Antagonists | 3 | 2025 | 68 | 0.480 |
Why?
|
| Medical Oncology | 1 | 2019 | 331 | 0.480 |
Why?
|
| Popliteal Artery | 3 | 2026 | 62 | 0.470 |
Why?
|
| Endpoint Determination | 2 | 2026 | 84 | 0.460 |
Why?
|
| Enzyme Inhibitors | 5 | 2014 | 820 | 0.460 |
Why?
|
| Pragmatic Clinical Trials as Topic | 4 | 2025 | 133 | 0.460 |
Why?
|
| Aminobutyrates | 2 | 2026 | 31 | 0.450 |
Why?
|
| Patient Readmission | 1 | 2021 | 765 | 0.450 |
Why?
|
| Ulcer | 2 | 2021 | 37 | 0.450 |
Why?
|
| Hematoma | 2 | 2021 | 61 | 0.440 |
Why?
|
| Angioplasty, Balloon | 4 | 2025 | 93 | 0.440 |
Why?
|
| Ankle Brachial Index | 5 | 2025 | 41 | 0.430 |
Why?
|
| Angioplasty | 2 | 2026 | 50 | 0.430 |
Why?
|
| Antibodies, Monoclonal, Humanized | 5 | 2023 | 990 | 0.430 |
Why?
|
| Non-ST Elevated Myocardial Infarction | 3 | 2019 | 26 | 0.430 |
Why?
|
| Benzazepines | 3 | 2019 | 35 | 0.420 |
Why?
|
| Apolipoprotein A-I | 2 | 2024 | 39 | 0.410 |
Why?
|
| Clinical Trials, Phase III as Topic | 8 | 2022 | 116 | 0.410 |
Why?
|
| Thiophenes | 2 | 2011 | 121 | 0.400 |
Why?
|
| Diabetic Cardiomyopathies | 3 | 2019 | 34 | 0.400 |
Why?
|
| Peptide Fragments | 3 | 2026 | 691 | 0.400 |
Why?
|
| Antibodies, Monoclonal | 2 | 2018 | 1505 | 0.400 |
Why?
|
| Global Health | 4 | 2021 | 401 | 0.380 |
Why?
|
| Enoxaparin | 3 | 2025 | 68 | 0.380 |
Why?
|
| Ranolazine | 7 | 2014 | 23 | 0.380 |
Why?
|
| Lecithins | 2 | 2022 | 5 | 0.370 |
Why?
|
| Pregnancy-Associated Plasma Protein-A | 1 | 2012 | 14 | 0.370 |
Why?
|
| Life Style | 1 | 2015 | 481 | 0.370 |
Why?
|
| Venous Thrombosis | 3 | 2025 | 193 | 0.360 |
Why?
|
| Comorbidity | 4 | 2025 | 1652 | 0.360 |
Why?
|
| MicroRNAs | 3 | 2023 | 689 | 0.360 |
Why?
|
| Intracranial Hemorrhages | 5 | 2018 | 101 | 0.360 |
Why?
|
| Receptor, PAR-1 | 5 | 2019 | 17 | 0.360 |
Why?
|
| American Heart Association | 5 | 2026 | 356 | 0.360 |
Why?
|
| Exercise Therapy | 5 | 2026 | 475 | 0.360 |
Why?
|
| Retrospective Studies | 12 | 2026 | 17149 | 0.350 |
Why?
|
| Diabetes Mellitus, Experimental | 2 | 2023 | 185 | 0.350 |
Why?
|
| Cohort Studies | 10 | 2022 | 5957 | 0.350 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 2012 | 151 | 0.340 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2021 | 2754 | 0.340 |
Why?
|
| Thrombin | 3 | 2021 | 167 | 0.320 |
Why?
|
| Angina Pectoris | 2 | 2009 | 75 | 0.310 |
Why?
|
| Health Care Costs | 2 | 2026 | 425 | 0.310 |
Why?
|
| Angioplasty, Balloon, Coronary | 2 | 2009 | 155 | 0.300 |
Why?
|
| Exercise Tolerance | 2 | 2025 | 282 | 0.290 |
Why?
|
| Appetite Depressants | 2 | 2019 | 19 | 0.290 |
Why?
|
| Chronic Disease | 5 | 2025 | 1810 | 0.280 |
Why?
|
| Thromboembolism | 3 | 2024 | 126 | 0.270 |
Why?
|
| Registries | 8 | 2025 | 2392 | 0.270 |
Why?
|
| Troponin | 3 | 2020 | 49 | 0.270 |
Why?
|
| Risk | 5 | 2019 | 911 | 0.270 |
Why?
|
| Coronary Artery Bypass | 3 | 2016 | 267 | 0.270 |
Why?
|
| Hospital Mortality | 3 | 2021 | 1033 | 0.260 |
Why?
|
| Europe | 3 | 2021 | 419 | 0.260 |
Why?
|
| Exercise | 2 | 2021 | 2183 | 0.260 |
Why?
|
| Ticlopidine | 5 | 2016 | 51 | 0.260 |
Why?
|
| Dipeptidyl-Peptidase IV Inhibitors | 2 | 2018 | 46 | 0.260 |
Why?
|
| Prevalence | 6 | 2025 | 2839 | 0.260 |
Why?
|
| Adult | 21 | 2025 | 40489 | 0.250 |
Why?
|
| Metabolic Syndrome | 2 | 2021 | 354 | 0.250 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 2 | 2026 | 228 | 0.250 |
Why?
|
| Combined Modality Therapy | 4 | 2020 | 1268 | 0.250 |
Why?
|
| Ventricular Function | 1 | 2006 | 54 | 0.250 |
Why?
|
| Antineoplastic Agents, Immunological | 2 | 2019 | 201 | 0.240 |
Why?
|
| Tissue Scaffolds | 2 | 2026 | 223 | 0.240 |
Why?
|
| Internationality | 3 | 2022 | 154 | 0.240 |
Why?
|
| Severity of Illness Index | 4 | 2025 | 2922 | 0.240 |
Why?
|
| Tetrazoles | 1 | 2026 | 49 | 0.230 |
Why?
|
| Chagas Cardiomyopathy | 1 | 2026 | 27 | 0.230 |
Why?
|
| Biphenyl Compounds | 3 | 2026 | 66 | 0.230 |
Why?
|
| Pyridones | 2 | 2025 | 201 | 0.230 |
Why?
|
| Telemedicine | 2 | 2025 | 957 | 0.230 |
Why?
|
| Heparin, Low-Molecular-Weight | 2 | 2023 | 36 | 0.220 |
Why?
|
| Saphenous Vein | 1 | 2025 | 37 | 0.220 |
Why?
|
| Diabetic Nephropathies | 2 | 2019 | 318 | 0.220 |
Why?
|
| Colorado | 2 | 2025 | 4558 | 0.220 |
Why?
|
| Obesity | 4 | 2019 | 3070 | 0.220 |
Why?
|
| Antineoplastic Agents | 2 | 2026 | 2201 | 0.220 |
Why?
|
| Pulmonary Embolism | 2 | 2025 | 241 | 0.220 |
Why?
|
| Health Resources | 1 | 2026 | 130 | 0.220 |
Why?
|
| Arterial Occlusive Diseases | 1 | 2025 | 90 | 0.210 |
Why?
|
| Cross-Sectional Studies | 3 | 2025 | 5870 | 0.210 |
Why?
|
| Aortic Aneurysm | 2 | 2016 | 70 | 0.210 |
Why?
|
| Injections, Subcutaneous | 1 | 2025 | 168 | 0.210 |
Why?
|
| Walk Test | 1 | 2025 | 80 | 0.210 |
Why?
|
| Pravastatin | 2 | 2016 | 44 | 0.210 |
Why?
|
| Disease Progression | 4 | 2026 | 2847 | 0.210 |
Why?
|
| Angiography | 2 | 2024 | 208 | 0.210 |
Why?
|
| Recovery of Function | 3 | 2025 | 715 | 0.210 |
Why?
|
| Cardiovascular System | 2 | 2022 | 136 | 0.210 |
Why?
|
| Multifactorial Inheritance | 1 | 2025 | 190 | 0.200 |
Why?
|
| Immunotherapy | 2 | 2019 | 662 | 0.200 |
Why?
|
| Heptanoic Acids | 2 | 2015 | 67 | 0.200 |
Why?
|
| Ventricular Remodeling | 1 | 2026 | 275 | 0.200 |
Why?
|
| Blood Pressure | 3 | 2025 | 1766 | 0.200 |
Why?
|
| Arteries | 2 | 2022 | 258 | 0.200 |
Why?
|
| Psychiatric Rehabilitation | 1 | 2023 | 4 | 0.200 |
Why?
|
| Thromboplastin | 1 | 2023 | 64 | 0.190 |
Why?
|
| Angina, Unstable | 3 | 2013 | 82 | 0.190 |
Why?
|
| Age Factors | 5 | 2024 | 3329 | 0.190 |
Why?
|
| Sex Factors | 3 | 2025 | 2104 | 0.190 |
Why?
|
| Computed Tomography Angiography | 1 | 2024 | 146 | 0.190 |
Why?
|
| Echocardiography | 2 | 2024 | 644 | 0.190 |
Why?
|
| Pyrroles | 2 | 2015 | 213 | 0.180 |
Why?
|
| Sensitivity and Specificity | 4 | 2014 | 1995 | 0.180 |
Why?
|
| Coronary Angiography | 1 | 2024 | 324 | 0.180 |
Why?
|
| Liraglutide | 1 | 2022 | 32 | 0.180 |
Why?
|
| Numbers Needed To Treat | 1 | 2021 | 7 | 0.180 |
Why?
|
| Thiazoles | 1 | 2022 | 139 | 0.180 |
Why?
|
| Symporters | 1 | 2022 | 48 | 0.180 |
Why?
|
| Renal Dialysis | 1 | 2026 | 465 | 0.180 |
Why?
|
| Mobility Limitation | 1 | 2022 | 66 | 0.170 |
Why?
|
| Kidney | 2 | 2020 | 1495 | 0.170 |
Why?
|
| Cardiomyopathies | 1 | 2025 | 334 | 0.170 |
Why?
|
| Predictive Value of Tests | 5 | 2018 | 2117 | 0.170 |
Why?
|
| Warfarin | 1 | 2022 | 173 | 0.170 |
Why?
|
| Early Termination of Clinical Trials | 1 | 2021 | 18 | 0.170 |
Why?
|
| Doxorubicin | 1 | 2023 | 398 | 0.170 |
Why?
|
| Inflammation | 3 | 2023 | 2870 | 0.170 |
Why?
|
| Myocardial Revascularization | 4 | 2021 | 84 | 0.170 |
Why?
|
| Frailty | 1 | 2024 | 200 | 0.170 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2023 | 228 | 0.160 |
Why?
|
| Aortic Valve Stenosis | 1 | 2024 | 255 | 0.160 |
Why?
|
| Precision Medicine | 1 | 2025 | 454 | 0.160 |
Why?
|
| Placebos | 1 | 2021 | 193 | 0.160 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2022 | 244 | 0.160 |
Why?
|
| Societies, Medical | 1 | 2025 | 890 | 0.160 |
Why?
|
| Drug Therapy | 1 | 2021 | 80 | 0.160 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2021 | 176 | 0.160 |
Why?
|
| Heart Diseases | 2 | 2016 | 341 | 0.160 |
Why?
|
| Lipids | 1 | 2025 | 706 | 0.160 |
Why?
|
| Genetic Variation | 1 | 2025 | 985 | 0.160 |
Why?
|
| Medication Adherence | 1 | 2024 | 540 | 0.160 |
Why?
|
| Methylamines | 1 | 2020 | 40 | 0.160 |
Why?
|
| Cardiotoxicity | 3 | 2026 | 34 | 0.150 |
Why?
|
| Rural Population | 1 | 2025 | 657 | 0.150 |
Why?
|
| Kidney Failure, Chronic | 1 | 2026 | 597 | 0.150 |
Why?
|
| Vaccination | 2 | 2025 | 1419 | 0.150 |
Why?
|
| Survival Analysis | 2 | 2014 | 1370 | 0.150 |
Why?
|
| Blood Coagulation | 1 | 2021 | 268 | 0.150 |
Why?
|
| Pharmaceutical Preparations | 1 | 2021 | 170 | 0.150 |
Why?
|
| Osteoporosis, Postmenopausal | 1 | 2019 | 40 | 0.150 |
Why?
|
| Glucagon-Like Peptide Receptors | 1 | 2019 | 1 | 0.150 |
Why?
|
| Lipoprotein(a) | 1 | 2020 | 69 | 0.150 |
Why?
|
| Reproducibility of Results | 4 | 2023 | 3414 | 0.150 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2022 | 234 | 0.150 |
Why?
|
| Heart | 1 | 2023 | 626 | 0.150 |
Why?
|
| Serotonin 5-HT2 Receptor Agonists | 1 | 2019 | 6 | 0.150 |
Why?
|
| Pilot Projects | 1 | 2025 | 1886 | 0.150 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2026 | 881 | 0.140 |
Why?
|
| Patient Education as Topic | 1 | 2024 | 771 | 0.140 |
Why?
|
| Bone Density Conservation Agents | 1 | 2019 | 81 | 0.140 |
Why?
|
| Appetite Regulation | 1 | 2019 | 31 | 0.140 |
Why?
|
| Platelet Glycoprotein GPIIb-IIIa Complex | 2 | 2009 | 25 | 0.140 |
Why?
|
| Sleep Apnea Syndromes | 1 | 2020 | 96 | 0.140 |
Why?
|
| Pharmacovigilance | 1 | 2018 | 23 | 0.140 |
Why?
|
| Drug Approval | 2 | 2019 | 91 | 0.140 |
Why?
|
| Cardiac Rehabilitation | 1 | 2019 | 46 | 0.140 |
Why?
|
| Hemoglobins | 1 | 2021 | 381 | 0.140 |
Why?
|
| Coronary Disease | 2 | 2018 | 381 | 0.140 |
Why?
|
| Adamantane | 1 | 2018 | 18 | 0.140 |
Why?
|
| Microcirculation | 1 | 2019 | 141 | 0.140 |
Why?
|
| Weight Loss | 3 | 2019 | 839 | 0.140 |
Why?
|
| Dipeptides | 1 | 2018 | 56 | 0.140 |
Why?
|
| Polyethylene Glycols | 1 | 2023 | 652 | 0.140 |
Why?
|
| Platelet Activation | 2 | 2017 | 98 | 0.140 |
Why?
|
| Canagliflozin | 1 | 2018 | 10 | 0.140 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 1 | 2018 | 81 | 0.140 |
Why?
|
| Reoperation | 1 | 2021 | 624 | 0.130 |
Why?
|
| Ischemic Attack, Transient | 2 | 2015 | 71 | 0.130 |
Why?
|
| Research Personnel | 1 | 2020 | 185 | 0.130 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2018 | 104 | 0.130 |
Why?
|
| Anti-Obesity Agents | 1 | 2018 | 67 | 0.130 |
Why?
|
| Calibration | 1 | 2018 | 151 | 0.130 |
Why?
|
| Young Adult | 6 | 2024 | 14122 | 0.130 |
Why?
|
| Kidney Neoplasms | 1 | 2022 | 412 | 0.130 |
Why?
|
| Clinical Chemistry Tests | 2 | 2015 | 6 | 0.130 |
Why?
|
| Uracil | 1 | 2017 | 36 | 0.130 |
Why?
|
| Inpatients | 1 | 2021 | 547 | 0.130 |
Why?
|
| Morbidity | 1 | 2018 | 322 | 0.130 |
Why?
|
| Intestines | 1 | 2020 | 357 | 0.130 |
Why?
|
| Glycopeptides | 2 | 2014 | 44 | 0.130 |
Why?
|
| Practice Guidelines as Topic | 1 | 2025 | 1569 | 0.120 |
Why?
|
| Pandemics | 2 | 2022 | 1700 | 0.120 |
Why?
|
| Smoking | 2 | 2021 | 1467 | 0.120 |
Why?
|
| Healthcare Disparities | 1 | 2023 | 736 | 0.120 |
Why?
|
| Overweight | 2 | 2018 | 606 | 0.120 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2023 | 1961 | 0.120 |
Why?
|
| Biological Assay | 2 | 2015 | 128 | 0.120 |
Why?
|
| Pericarditis | 1 | 2016 | 11 | 0.120 |
Why?
|
| Vascular Patency | 1 | 2016 | 121 | 0.120 |
Why?
|
| Aortitis | 1 | 2016 | 10 | 0.120 |
Why?
|
| Marketing | 1 | 2016 | 23 | 0.120 |
Why?
|
| Vascular Grafting | 1 | 2016 | 15 | 0.120 |
Why?
|
| Cyclopropanes | 1 | 2016 | 83 | 0.120 |
Why?
|
| Guideline Adherence | 1 | 2020 | 586 | 0.120 |
Why?
|
| Uncertainty | 1 | 2016 | 145 | 0.120 |
Why?
|
| Diabetic Angiopathies | 1 | 2018 | 262 | 0.120 |
Why?
|
| Down-Regulation | 1 | 2017 | 616 | 0.110 |
Why?
|
| Piperidines | 1 | 2017 | 219 | 0.110 |
Why?
|
| Multimodal Imaging | 1 | 2016 | 129 | 0.110 |
Why?
|
| Adiponectin | 1 | 2017 | 240 | 0.110 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2016 | 265 | 0.110 |
Why?
|
| Algorithms | 2 | 2020 | 1844 | 0.110 |
Why?
|
| Simvastatin | 1 | 2015 | 59 | 0.110 |
Why?
|
| France | 3 | 2019 | 40 | 0.110 |
Why?
|
| Benzaldehydes | 1 | 2014 | 10 | 0.110 |
Why?
|
| Oximes | 1 | 2014 | 26 | 0.110 |
Why?
|
| ROC Curve | 2 | 2014 | 618 | 0.110 |
Why?
|
| International Cooperation | 2 | 2013 | 197 | 0.110 |
Why?
|
| Muscle, Skeletal | 1 | 2025 | 1788 | 0.110 |
Why?
|
| Decision Support Techniques | 1 | 2018 | 461 | 0.100 |
Why?
|
| Genome-Wide Association Study | 1 | 2020 | 1374 | 0.100 |
Why?
|
| Mental Disorders | 1 | 2023 | 1154 | 0.100 |
Why?
|
| Periodicals as Topic | 1 | 2016 | 206 | 0.100 |
Why?
|
| Hypoglycemia | 1 | 2018 | 479 | 0.100 |
Why?
|
| Bacteria | 1 | 2020 | 894 | 0.100 |
Why?
|
| Child, Preschool | 3 | 2024 | 11790 | 0.100 |
Why?
|
| Fatty Acid-Binding Proteins | 1 | 2013 | 79 | 0.100 |
Why?
|
| Adolescent | 5 | 2024 | 22409 | 0.100 |
Why?
|
| Social Media | 1 | 2016 | 167 | 0.100 |
Why?
|
| Emergency Service, Hospital | 3 | 2017 | 2325 | 0.100 |
Why?
|
| Infusions, Intravenous | 2 | 2024 | 422 | 0.100 |
Why?
|
| Veterans | 2 | 2022 | 1614 | 0.090 |
Why?
|
| Sleep | 1 | 2020 | 890 | 0.090 |
Why?
|
| C-Reactive Protein | 2 | 2016 | 420 | 0.090 |
Why?
|
| Calgranulin B | 1 | 2012 | 10 | 0.090 |
Why?
|
| Blood Proteins | 1 | 2014 | 230 | 0.090 |
Why?
|
| Calgranulin A | 1 | 2012 | 11 | 0.090 |
Why?
|
| Pregnancy Proteins | 1 | 2012 | 35 | 0.090 |
Why?
|
| Osteoprotegerin | 1 | 2012 | 22 | 0.090 |
Why?
|
| Angiotensin Receptor Antagonists | 2 | 2026 | 115 | 0.090 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2020 | 771 | 0.090 |
Why?
|
| Internship and Residency | 1 | 2022 | 1262 | 0.080 |
Why?
|
| Neovascularization, Physiologic | 2 | 2023 | 191 | 0.080 |
Why?
|
| Obesity, Abdominal | 1 | 2011 | 46 | 0.080 |
Why?
|
| Internet | 1 | 2016 | 698 | 0.080 |
Why?
|
| Models, Biological | 1 | 2018 | 1811 | 0.080 |
Why?
|
| Protein Precursors | 2 | 2014 | 136 | 0.080 |
Why?
|
| Risk Reduction Behavior | 2 | 2026 | 215 | 0.080 |
Why?
|
| Primary Prevention | 2 | 2025 | 217 | 0.080 |
Why?
|
| Femoral Artery | 2 | 2022 | 190 | 0.080 |
Why?
|
| Electronic Health Records | 1 | 2018 | 1176 | 0.080 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2016 | 971 | 0.080 |
Why?
|
| Receptors, Cell Surface | 1 | 2011 | 370 | 0.070 |
Why?
|
| Chi-Square Distribution | 1 | 2010 | 524 | 0.070 |
Why?
|
| Subclavian Steal Syndrome | 1 | 2009 | 3 | 0.070 |
Why?
|
| Bayes Theorem | 2 | 2023 | 426 | 0.070 |
Why?
|
| Troponin C | 1 | 2008 | 3 | 0.070 |
Why?
|
| Natriuretic Peptides | 1 | 2008 | 9 | 0.070 |
Why?
|
| Multivariate Analysis | 1 | 2012 | 1537 | 0.070 |
Why?
|
| Exercise Test | 2 | 2025 | 626 | 0.070 |
Why?
|
| Child | 3 | 2024 | 22600 | 0.070 |
Why?
|
| Platelet Function Tests | 2 | 2018 | 35 | 0.070 |
Why?
|
| Death | 2 | 2020 | 131 | 0.060 |
Why?
|
| Endothelial Cells | 2 | 2023 | 864 | 0.060 |
Why?
|
| Body Weight | 2 | 2023 | 968 | 0.060 |
Why?
|
| Hemodialysis, Home | 1 | 2026 | 9 | 0.060 |
Why?
|
| Valsartan | 1 | 2026 | 32 | 0.060 |
Why?
|
| Factor Xa | 1 | 2025 | 34 | 0.060 |
Why?
|
| Pregnancy | 2 | 2024 | 7122 | 0.060 |
Why?
|
| Naphthyridines | 1 | 2025 | 20 | 0.060 |
Why?
|
| Heart Ventricles | 1 | 2010 | 751 | 0.060 |
Why?
|
| Spironolactone | 1 | 2025 | 39 | 0.060 |
Why?
|
| Body Mass Index | 3 | 2023 | 2419 | 0.060 |
Why?
|
| Emergency Medical Services | 1 | 2012 | 695 | 0.060 |
Why?
|
| Phosphocreatine | 1 | 2025 | 44 | 0.050 |
Why?
|
| Drug Combinations | 1 | 2026 | 393 | 0.050 |
Why?
|
| Gangrene | 1 | 2024 | 11 | 0.050 |
Why?
|
| Cost-Benefit Analysis | 2 | 2018 | 638 | 0.050 |
Why?
|
| Hypotension | 1 | 2025 | 126 | 0.050 |
Why?
|
| Thrombophilia | 1 | 2025 | 89 | 0.050 |
Why?
|
| Coronary Stenosis | 1 | 2024 | 38 | 0.050 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2025 | 117 | 0.050 |
Why?
|
| Patient Discharge | 1 | 2010 | 985 | 0.050 |
Why?
|
| Inhibin-beta Subunits | 1 | 2023 | 6 | 0.050 |
Why?
|
| Plaque, Atherosclerotic | 1 | 2024 | 60 | 0.050 |
Why?
|
| Case-Control Studies | 2 | 2022 | 3603 | 0.050 |
Why?
|
| Inhibins | 1 | 2023 | 41 | 0.050 |
Why?
|
| Everolimus | 1 | 2023 | 112 | 0.050 |
Why?
|
| Soluble Guanylyl Cyclase | 1 | 2022 | 15 | 0.050 |
Why?
|
| Receptors, CXCR4 | 1 | 2023 | 91 | 0.050 |
Why?
|
| Recombinant Proteins | 1 | 2025 | 1363 | 0.050 |
Why?
|
| Necrosis | 1 | 2023 | 243 | 0.050 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2025 | 625 | 0.040 |
Why?
|
| Therapeutics | 1 | 2022 | 14 | 0.040 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 2022 | 77 | 0.040 |
Why?
|
| Multimorbidity | 1 | 2022 | 64 | 0.040 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2025 | 480 | 0.040 |
Why?
|
| Evidence-Based Medicine | 2 | 2017 | 732 | 0.040 |
Why?
|
| Pyrazoles | 1 | 2025 | 512 | 0.040 |
Why?
|
| Animals | 5 | 2023 | 37948 | 0.040 |
Why?
|
| Mice | 3 | 2023 | 18261 | 0.040 |
Why?
|
| Coated Materials, Biocompatible | 1 | 2021 | 65 | 0.040 |
Why?
|
| Sodium | 1 | 2022 | 198 | 0.040 |
Why?
|
| Observational Studies as Topic | 1 | 2021 | 131 | 0.040 |
Why?
|
| RNA, Small Interfering | 1 | 2023 | 631 | 0.040 |
Why?
|
| Genotyping Techniques | 1 | 2020 | 70 | 0.040 |
Why?
|
| Transforming Growth Factor beta | 1 | 2023 | 475 | 0.040 |
Why?
|
| Drug Labeling | 1 | 2019 | 37 | 0.040 |
Why?
|
| Research Support as Topic | 1 | 2020 | 79 | 0.040 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2024 | 431 | 0.040 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2022 | 550 | 0.040 |
Why?
|
| Spinal Fractures | 1 | 2019 | 75 | 0.040 |
Why?
|
| Infant | 2 | 2024 | 10023 | 0.040 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2018 | 76 | 0.040 |
Why?
|
| Immunosuppressive Agents | 1 | 2023 | 834 | 0.040 |
Why?
|
| NF-kappa B | 1 | 2022 | 657 | 0.040 |
Why?
|
| Osteoporotic Fractures | 1 | 2019 | 61 | 0.040 |
Why?
|
| Aorta | 1 | 2021 | 427 | 0.040 |
Why?
|
| Hip Fractures | 1 | 2019 | 86 | 0.040 |
Why?
|
| Republic of Korea | 1 | 2018 | 42 | 0.030 |
Why?
|
| Diet, Reducing | 1 | 2019 | 91 | 0.030 |
Why?
|
| New Zealand | 1 | 2018 | 54 | 0.030 |
Why?
|
| Retinal Diseases | 1 | 2019 | 101 | 0.030 |
Why?
|
| Aortic Valve Insufficiency | 1 | 2018 | 43 | 0.030 |
Why?
|
| Diuresis | 1 | 2018 | 10 | 0.030 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2019 | 133 | 0.030 |
Why?
|
| Advisory Committees | 1 | 2020 | 228 | 0.030 |
Why?
|
| Sweden | 1 | 2018 | 111 | 0.030 |
Why?
|
| Cerebral Infarction | 1 | 2018 | 47 | 0.030 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2025 | 2137 | 0.030 |
Why?
|
| Remission Induction | 1 | 2018 | 309 | 0.030 |
Why?
|
| Disease Susceptibility | 1 | 2019 | 342 | 0.030 |
Why?
|
| Logistic Models | 1 | 2022 | 2114 | 0.030 |
Why?
|
| Receptors, Purinergic P2Y12 | 1 | 2017 | 6 | 0.030 |
Why?
|
| Antiviral Agents | 1 | 2023 | 765 | 0.030 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2018 | 251 | 0.030 |
Why?
|
| Up-Regulation | 1 | 2020 | 848 | 0.030 |
Why?
|
| England | 1 | 2017 | 108 | 0.030 |
Why?
|
| Florida | 1 | 2017 | 117 | 0.030 |
Why?
|
| Machine Learning | 1 | 2022 | 587 | 0.030 |
Why?
|
| Delivery of Health Care | 1 | 2023 | 944 | 0.030 |
Why?
|
| Glucose | 1 | 2022 | 1033 | 0.030 |
Why?
|
| Marfan Syndrome | 1 | 2016 | 46 | 0.030 |
Why?
|
| Insulin | 2 | 2018 | 2502 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2024 | 2942 | 0.030 |
Why?
|
| Microfilament Proteins | 1 | 2017 | 136 | 0.030 |
Why?
|
| Health Promotion | 1 | 2022 | 771 | 0.030 |
Why?
|
| Cell Adhesion Molecules | 1 | 2017 | 178 | 0.030 |
Why?
|
| Bone Density | 1 | 2019 | 484 | 0.030 |
Why?
|
| Intensive Care Units | 1 | 2021 | 915 | 0.030 |
Why?
|
| Prediabetic State | 1 | 2018 | 247 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2024 | 2350 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2016 | 365 | 0.030 |
Why?
|
| Curriculum | 1 | 2022 | 1063 | 0.030 |
Why?
|
| Diethylamines | 1 | 2014 | 5 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2017 | 835 | 0.030 |
Why?
|
| Phosphoproteins | 1 | 2017 | 339 | 0.030 |
Why?
|
| Publishing | 1 | 2016 | 115 | 0.030 |
Why?
|
| Long-Term Care | 1 | 2015 | 117 | 0.030 |
Why?
|
| Fractures, Bone | 1 | 2019 | 417 | 0.030 |
Why?
|
| Drug Monitoring | 1 | 2018 | 396 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2017 | 1076 | 0.030 |
Why?
|
| Mortality | 1 | 2017 | 377 | 0.030 |
Why?
|
| Transcription Factors | 1 | 2022 | 1726 | 0.030 |
Why?
|
| Metformin | 1 | 2018 | 320 | 0.030 |
Why?
|
| Sodium Channel Blockers | 1 | 2014 | 23 | 0.030 |
Why?
|
| Atrial Natriuretic Factor | 1 | 2014 | 55 | 0.030 |
Why?
|
| United States Food and Drug Administration | 1 | 2015 | 205 | 0.030 |
Why?
|
| Fatty Acid Binding Protein 3 | 1 | 2013 | 6 | 0.030 |
Why?
|
| Clinical Competence | 1 | 2022 | 1237 | 0.030 |
Why?
|
| Pyrimidinones | 1 | 2014 | 125 | 0.030 |
Why?
|
| Sulfides | 1 | 2014 | 92 | 0.020 |
Why?
|
| Limit of Detection | 1 | 2013 | 95 | 0.020 |
Why?
|
| Massachusetts | 1 | 2014 | 180 | 0.020 |
Why?
|
| Aortic Valve | 1 | 2016 | 364 | 0.020 |
Why?
|
| Placenta Growth Factor | 1 | 2012 | 26 | 0.020 |
Why?
|
| Norway | 1 | 2012 | 41 | 0.020 |
Why?
|
| Retreatment | 1 | 2012 | 77 | 0.020 |
Why?
|
| Creatinine | 1 | 2014 | 509 | 0.020 |
Why?
|
| Interleukin-1 Receptor-Like 1 Protein | 1 | 2011 | 22 | 0.020 |
Why?
|
| Waist Circumference | 1 | 2011 | 141 | 0.020 |
Why?
|
| Anthropometry | 1 | 2011 | 197 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2022 | 6399 | 0.020 |
Why?
|
| Creatine Kinase, MB Form | 1 | 2009 | 6 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2023 | 5185 | 0.020 |
Why?
|
| Atherectomy | 1 | 2008 | 37 | 0.020 |
Why?
|
| Hypertension, Pulmonary | 1 | 2018 | 1948 | 0.020 |
Why?
|
| Hemodynamics | 1 | 2011 | 1113 | 0.020 |
Why?
|
| Preoperative Care | 1 | 2008 | 379 | 0.010 |
Why?
|
| Research Design | 1 | 2009 | 1129 | 0.010 |
Why?
|